Resolution Mechanisms in Acute Inflammation: Resolution Pharmacology

急性炎症的消退机制：消退药理学

• 批准号: 8245841
• 负责人: Charles Nicholas Serhan
• 金额: $ 136.11万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2016-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8245841
• 关键词: Abbreviations; Accounting; Acute; Address; Agonist; Alzheimer' s Disease; Anti-Inflammatory Agents; Anti-inflammatory; Apoptotic; Area; Aspirin; Asthma; Awareness; Biochemical; Boxing; CD59 Antigen; Cardiovascular system; Caring; Chemicals; Chronic; Clinical; Coin; Communication; Communities; Containment; Development; Diabetes Mellitus; Disease; Disease model; Docosahexaenoic Acids; Eicosapentaenoic Acid; Epithelial; Epithelial Cells; Epithelium; Event; Failure; Family; Funding; Future; Glossary; Goals; Grant; Health; Healthcare; Homeostasis; Human; Immunosuppression; Inflammation; Inflammatory; Inflammatory Bowel Diseases; Inflammatory Response; Injury; Interdisciplinary Study; Invaded; Knowledge; LOX gene; Laboratories; Lead; Learning; Length of Stay; Leukocytes; Leukotrienes; Lipids; Lipoxins; Lipoxygenase; Liquid Chromatography; Mediator of activation protein; Medicine; Microbe; Mission; Molecular; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; Natural Immunity; Omega-3 Fatty Acids; Operative Surgical Procedures; Oral; Organ; Organic Synthesis; Organism; Pathway interactions; Patient Care; Performance; Phagocytes; Phagocytosis; Pharmacology; Phase; Physiological; Principal Investigator; Process; Prostaglandins; Public Health; Research Infrastructure; Research Personnel; Resolution; Role; Sepsis; Series; Signal Transduction; Structure; Surface; System; Testing; Therapeutic; Tissues; Translations; Trauma; United States National Institutes of Health; Work; Yang; base; clinical practice; design; economic impact; effective therapy; experience; human disease; human tissue; improved; in vivo; injured; insight; lipid mediator; macrophage; meetings; microbial; mimetics; multidisciplinary; neuroprotectin D1; neutrophil; novel; novel strategies; novel therapeutic intervention; pre-clinical; prevent; programs; repaired; response; scale up; small molecule; tandem mass spectrometry; uptake

DESCRIPTION (provided by applicant): In many human conditions (e.g. inflammatory bowel disease, sepsis, multi-organ injury and failure), the progression from acute inflammatory insult to either resolution or chronicity remains impossible to predict. Our recent findings indicate that resolution of local inflammation involves active resolution circuits that generate a novel genus of potent Specialized Pro-Resolving Mediators (SPM). SPM are comprised of distinct structural families of lipid mediators (LM) including resolvins, protectins and maresins derived from essential omega-3 fatty acids. Novel SPM that are potent anti-inflammatories also stimulate uptake of apoptotic neutrophils, microbial containment and their clearance by phagocytes and mucosal epithelia. These findings reveal an urgent clinical need to navigate resolution to establish fundamental mechanisms in resolution pharmacology. To address this health mission, a multidisciplinary team of experts is assembled in this program project that will use a systematic approach to elucidate cellular and molecular mechanisms in self-limited experimental systems. Our team and overall project is focused on elucidating programmed resolution of acute inflammation with an emphasis on LM, SPM and resolution pharmacology for new treatments. Ongoing studies give rise to an overarching hypothesis tested by four highly complementary integrated projects with synergistic approaches. The overall novel hypothesis addressed is: Resolvins, protectins and maresins constitute a new genus of SPM that temporally regulate endogenous anti inflammatory and pro-resolving pathways. SPM govern resolution via regulated leukocyte responses, enhanced mucosal defense and bacterial containment these molecular events can be harnessed for novel resolution pharmacology to treat diseases. This P01 team consists of 4 projects, 2 scientific cores and an advisory unit focused on establishing LM-resolution metabolome, stereo-controlled synthesis of SPM and their specific mechanisms in resolution, anti-inflammatory and clearance pathways. Selected synthetic SPM will be scaled-up for demonstration of their unique mode of action in vivo in a resolution pharmacology core using experimental disease models. Our broad goal is to bring forth new treatments in resolution.

描述（由申请人提供）：在许多人类疾病（如炎症性肠病、败血症、多器官损伤和衰竭）中，从急性炎症性损伤到缓解或慢性的进展仍然无法预测。我们最近的研究结果表明，局部炎症的解决涉及主动解决电路，产生一种新的强效的Specialized Pro-Resolving Mediators （SPM）。SPM由不同结构家族的脂质介质（LM）组成，包括从必需的omega-3脂肪酸中提取的溶解蛋白、保护蛋白和蛋白。新型SPM是有效的抗炎药，也刺激摄取凋亡的中性粒细胞，微生物遏制和它们的清除吞噬细胞和粘膜上皮。这些发现揭示了迫切的临床需要导航分辨率，以建立分辨率药理学的基本机制。为了完成这一健康使命，一个多学科专家团队将在这个项目中集合，他们将使用系统的方法来阐明自我限制实验系统中的细胞和分子机制。我们的团队和整个项目的重点是阐明急性炎症的程序化解决方案，重点是LM， SPM和解决药理学的新治疗方法。正在进行的研究产生了一个总体假设，四个高度互补的综合项目采用协同方法进行了测试。解决的整体新假设是：溶解蛋白，保护蛋白和蛋白构成一个新的SPM属，暂时调节内源性抗炎和促溶解途径。SPM通过调节白细胞反应，增强粘膜防御和细菌遏制来控制分辨率，这些分子事件可以用于新型分辨率药理学治疗疾病。该P01团队包括4个项目，2个科学核心和1个咨询单位，重点建立lm -分辨率代谢组，立体控制合成SPM及其在分辨率，抗炎和清除途径中的特定机制。选定的合成SPM将扩大规模，以证明其独特的作用模式在体内的解决药理学核心使用实验疾病模型。我们的大目标是提出解决问题的新方法。